Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2B Study to Determine Efficacy of HRX215, a First Generation MKK4 Inhibitor Drug, in Improving Regeneration of the Remnant Liver After Portal Vein Embolization (PVE) of Colorectal Liver Metastasis (CRLM)

NCT07612007 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT07612007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07612007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2B Study to Determine Efficacy of HRX215, a First Generation MKK4 Inhibitor Drug, in Improving Regeneration of the Remnant Liver After Portal Vein Embolization (PVE) of Colorectal Liver Metastasis (CRLM)
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
November 1, 2028
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal carcinoma, metastatic malignant neoplasm in the liver, resectable colorectal carcinoma, stage iv colorectal cancer ajcc v8